Skip to main content
Milind Javle, MD, Oncology, Houston, TX, University of Texas M.D. Anderson Cancer Center

MilindMJavleMD

Oncology Houston, TX

Physician

Are you Dr. Javle?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 33 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Milind Javle, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Florida, and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

  • University at Buffalo
    University at BuffaloFellowship, Hematology and Medical Oncology, 1995 - 1998
  • University at Buffalo
    University at BuffaloResidency, Internal Medicine, 1993 - 1994
  • Grant Medical College
    Grant Medical CollegeClass of 1991

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • TX State Medical License
    TX State Medical License 2007 - 2024
  • OK State Medical License
    OK State Medical License 2020 - 2021
  • NY State Medical License
    NY State Medical License 1998 - 2007
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
  • Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020

Press Mentions

  • MD Anderson Research Highlights for August 11, 2021
    MD Anderson Research Highlights for August 11, 2021August 11th, 2021
  • The 4th OrigiMed International Summit Held in Shanghai
    The 4th OrigiMed International Summit Held in ShanghaiJune 8th, 2021
  • GSK, German Merck's $4.2B Bintrafusp Alfa Drug Flops Again, but Companies Squint to See Glimmers of Hope
    GSK, German Merck's $4.2B Bintrafusp Alfa Drug Flops Again, but Companies Squint to See Glimmers of HopeMarch 16th, 2021
  • Join now to see all

Hospital Affiliations